Towards Personalization: How Can Advanced Quantitative Methods Help Regulators, Reimbursement Agencies And Clinicians Make Better Decisions

October 4, 2018 Danielle Twigg

Individual and population health can be improved by better targeting of treatments. This personalization requires an understanding of how treatment effectiveness differs across patient subgroups. However, in RCTs the interpretation of subgroup analysis is challenging due to the risk of spurious “false positive” results arising from multiple testing, compounded by lack of power. The analysis of large observational data sets, and the application of biomics are becoming important but still pose significant analytic challenges. We will explore some advanced methods to address these issues.

Authors: Richard Grieve, Warren Stevens, Neil Hawkins, Anirban Basu

To find out more about this poster you can register to download it here after the ISPOR event.

 

Previous Article
Has The Nice HST Process Been A Success? Comparison With Other European HTA Bodies
Has The Nice HST Process Been A Success? Comparison With Other European HTA Bodies

Next Article
Time-Limited G-Ba Resolutions – A Tool To Appropriately Manage Reimbursement Of Innovative Therapies Receiving Expedited Regulatory Approval
Time-Limited G-Ba Resolutions – A Tool To Appropriately Manage Reimbursement Of Innovative Therapies Receiving Expedited Regulatory Approval